Oana Cristina Danciu

Multiomic Analysis Links Neighborhood Disadvantage to Inflammatory Proteins and Tumorigenic Markers in ER+ Breast Cancer Plasma and Tumor Samples

Hannah Heath, Ashlie Santaliz Casiano, Farizi Fazli, Hannah M. McGee et autres

High Resolution Image Download MS PowerPoint Slide Residing in disadvantaged neighborhoods has been linked to worsened survival among Black women with estrogen receptor-positive (ER+) breast cancer (BC), yet the underlying multiomic alterations remain underexplored. To investigate associations between neighborhood deprivation and pretreatment …

us (code pays fourni par la source)

Abstract P2-09-27: Alpelisib (BYL719) with continued endocrine therapy following progression on endocrine therapy in hormone receptor–positive, HER2-negative, PIK3CA-mutant metastatic breast cancer: A Big Ten Cancer Research Consortium Study (BTCRC-BRE19-409)

Darian Louthan, Marina Nasrin Sharifi, Oana Cristina Danciu, Jairam Krishnamurthy et autres

Abstract Background: Activating mutations in the PIK3CA gene are found in ∼40% of patients with hormone receptor-positive (HR+) breast cancer (BC). The p110α-specific PI3K inhibitor alpelisib (ALP) is FDA-approved in combination with fulvestrant (FUL) for treatment of patients with HR+ HER2 negative …

Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers

Sneha Deepak Phadke, Kathy D. Miller, Ami N. Shah, Oana Cristina Danciu et autres

PURPOSE: Metastatic triple negative breast cancer has a poor prognosis with limited targeted treatment options. In preclinical studies PI3K inhibition led to increased DNA damage and subsequent sensitization to PARP inhibition. This study aimed to investigate the safety and efficacy of the …

us (code pays fourni par la source)

Abstract 5753: Multi-omic analysis links neighborhood disadvantage to elevated stress hormones and tumorigenic markers in ER+ breast cancer patient plasma and tumor samples

Hannah Heath, Oana Cristina Danciu, Garth H. Rauscher, Natalie Pulliam et autres

Intro: Estrogen receptor positive (ER+) breast cancer (BC) patients living in disadvantaged neighborhoods experience worse survival compared with patients in advantaged neighborhoods. Chronic stress, indicated by elevated cortisol levels, may mediate this disparity by dysregulating inflammatory responses driving BC tumorigenesis. However, the …

us (code pays fourni par la source)

Abstract 3628: Associations between per and polyfluoroalkyl substances (PFAS) and inflammatory markers in a racially diverse cohort of breast cancer patients

Alicia Arredondo Eve, Ashlie Santaliz Casiano, Oana Cristina Danciu, Garth H. Rauscher et autres

Background: Per- and polyfluoroalkyl substances (PFAS) are persistent environmental pollutants known for their resistance to degradation and their potential to accumulate in biological systems. These compounds have been associated with various adverse health effects, including promoting cancer progression. Aim: This study aimed …

us (code pays fourni par la source)

Administrator, Provider, and Staff Perspectives on Implementing Acupuncture in Medically Underserved Breast Cancer Survivors

Hongjin Li, Ardith Zwyghuizen Doorenbos, Hannah Choi, Judith M. Schlaeger et autres

BACKGROUND: Breast cancer survivors on endocrine therapy frequently experience multiple symptoms that significantly impact their quality of life. Acupuncture has shown potential in managing these symptoms but remains less accessible for medically underserved populations. OBJECTIVE: This study aimed to explore the acceptability, …

us (code pays fourni par la source)

Feasibility and Acceptability of Integrating Acupuncture for Management of Multiple Symptoms in Medically Underserved Breast Cancer Survivors

Hongjin Li, Ardith Zwyghuizen Doorenbos, Zhengjia Chen, Hannah Choi et autres

BACKGROUND/OBJECTIVES: Breast cancer survivors undergoing long-term endocrine therapy often experience multiple symptoms, including pain, fatigue, sleep disturbance, hot flashes, anxiety, and depression. This study explored the feasibility and acceptability of integrating acupuncture for symptom management in medically underserved breast cancer survivors. METHODS: …

us (code pays fourni par la source)

Barriers and Facilitators to Integrating Acupuncture into the U.S. Health Care System: A Scoping Review

Hongjin Li, Juanita E. Darby, Ivy Akpotu, Judith M. Schlaeger et autres

Background: Acupuncture is a widely practiced complementary and integrative health modality that has multiple clinical applications. The use of acupuncture in the United States is rapidly increasing. Although studies have shown the efficacy and effectiveness of acupuncture for various ailments, the integration …

us (code pays fourni par la source)

Enhancing diverse representation in clinical studies: Recommendations from external subject matter experts (SMEs) and patients to optimize protocols, informed consent and study designs.

Gregory A. Vidal, Haiying Cheng, Andrea N. Curry, Oana Cristina Danciu et autres

e23004 Background: Well-characterized disparities in clinical research have disproportionately affected patients of color, particularly in underserved communities. To tackle these barriers, the Roche-Genentech U.S. Advancing Inclusive Research Site Alliance solicited feedback from external SMEs about recommendations for strategies and tactics to increase …

us (code pays fourni par la source)

Abemaciclib dose escalation to maintain intensity (ADE-MI).

Kevin Prescott, VK Gadi, Oana Cristina Danciu, Kent F. Hoskins et autres

TPS618 Background: Abemaciclib is a an oral CDK4/6 inhibitor that is FDA-approved as adjuvant therapy for certain patients with early-stage HR+HER2- breast cancer in combination with endocrine therapy. The major toxicity of abemaciclib is diarrhea, which often occurs within the first 6-8 …

us (code pays fourni par la source)

Risk of VTE in TNBC treated with neoadjuvant immunotherapy.

Ayesha Farooqui, Jeremy Kao, Marwah Wafa Farooqui, Oana Cristina Danciu

e12658 Background: Triple-negative breast cancer (TNBC) has limited treatment options. KEYNOTE 522 led to the approval of neoadjuvant (NT) Pembrolizumab in July 2021 changing the treatment paradigm for early stage TNBC. While improving pathologic complete response it also slightly increased treatment related …

us (code pays fourni par la source)

Abstract PO1-06-09: Phase 2 Trial with Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast CancersBig Ten Cancer Research Consortium BTCRC-BRE18-337

Sneha Deepak Phadke, Kari Braun Wisinski, Oana Cristina Danciu, Ami N. Shah et autres

Abstract Up to 2/3 of triple negative breast cancers (TNBC) have acquired defects in homologous recombination (HR) DNA repair, yet poly (ADP-ribose) polymerase inhibitor (PARPi) monotherapy has been largely ineffective in the absence of a germline BRCA 1/2 mutation (gBRCA1/2). Phosphoinositide-3-kinase (PI3K)/mTOR …

us (code pays fourni par la source)